

Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

2. *Late Applications:* Applications which do not meet the criteria in 1.a. or 1.b. above are considered late applications. Late applications will not be considered in the current competition and will be returned to the applicant.

#### Where To Obtain Additional Information

A complete program description and information on application procedures are contained in the application package. Business management technical assistance may be obtained from Gordon R. Clapp, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314, Mailstop E-18, Atlanta, Georgia 30305, telephone (404) 842-6508.

Programmatic technical assistance may be obtained from Pat McConnon, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), Mailstop C-12, 1600 Clifton Road, NE., Atlanta, Georgia

30333, telephone (404) 639-2175, Email Address: PJM2@CIDOD1.EM.CDC.GOV.

Please refer to Announcement Number 543 when requesting information regarding this program.

Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report, Stock No. 017-001-00473-1) referenced in the Introduction through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: July 17, 1995.

**Joseph R. Carter,**

*Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 95-18023 Filed 7-20-95; 8:45 am]

BILLING CODE 4163-18-P

#### Food and Drug Administration

[Docket No. 95N-0173]

**Procter & Gamble Pharmaceuticals, Inc., et al.; Withdrawal of Approval of NADA's**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of 16 new animal drug applications (NADA's). Fourteen NADA's are held by Procter & Gamble Pharmaceuticals, Inc., and one each is held by Lemmon Co. and Happy Jack, Inc. The firms notified the agency in writing that the animal drug products were no longer marketed and requested that the approval of the applications be withdrawn. In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the regulations by removing the entries which reflect approval of the NADA's.

**EFFECTIVE DATE:** July 31, 1995.

**FOR FURTHER INFORMATION CONTACT:** Mohammad I. Sharar, Center for Veterinary Medicine (HFV-216), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1722.

**SUPPLEMENTARY INFORMATION:** The sponsors of the applications listed in the table in this document have informed FDA that these animal drug products are no longer marketed and have requested that FDA withdraw approval of the applications.

NADA No.	Drug name	Sponsor name and address
10-158 .....	Furamazone, bismuth subsalicylate bolus .....	Procter & Gamble Pharmaceuticals, Inc., P.O. Box 191, Norwich, NY 13815
10-358 .....	Nitrofurantoin tablets and boluses .....	do
12-291 .....	Nitrofurantoin oral suspension .....	do
12-612 .....	Nitrofurazone, nifuroxime, diperodon hydrochloride (HCl) ear solution.	do
34-716 .....	Buquinolate .....	do
35-314 .....	Buquinolate and bacitracin zinc .....	do
35-315 .....	Buquinolate, bacitracin zinc, and penicillin .....	do
35-317 .....	Buquinolate and penicillin .....	do
35-327 .....	Buquinolate, bacitracin methylene disalicylate (bacitracin MD), and penicillin.	do
35-329 .....	Buquinolate and bacitracin MD .....	do
38-657 .....	Buquinolate and chlortetracycline .....	do
39-925 .....	Buquinolate and roxarsone combination .....	do
39-926 .....	Buquinolate and roxarsone .....	do
41-744 .....	Nitrofurantoin sodium injection .....	do
95-017 .....	Etorphine HCl injection and diprenorphine HCl in- jection.	Lemmon Co., Sellersville, PA 18960
115-580 .....	Piperazine adipate powder .....	Happy Jack, Snow Hill, NC 28580

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA's 10-158, 10-358, 12-291, 12-612, 34-716, 35-314, 35-315, 35-317, 35-327, 35-329, 38-657,

39-925, 39-926, 41-744, 95-017, 115-580, and all supplements and amendments thereto is hereby withdrawn, effective July 31, 1995..

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is removing 21 CFR 520.1560, 520.1560a, 520.1560b, 520.1801, 520.1801a, 522.1563, 524.1580a, 558.62(c)(2)(v), 558.105,

558.128(c)(5)(iii), 558.325(c)(3)(iv), 558.460(c)(2)(v), and 558.530(d)(3)(vii), and amending 21 CFR 510.600(c), 522.723, and 522.883 to reflect the withdrawal of approval of the above mentioned NADA's.

Dated: July 13, 1995.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 95-17924 Filed 7-20-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket Nos. 95P-0061, 95S-0117, 95S-0126, and 95S-0135]

**Patent Term Expiration Dates for Patents Extended by the Uruguay Round Agreements Act; Submission by Applicants of New Drug and New Animal Drug Applications**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing its position on patent information submitted by applicants of new drug applications (NDA's) and new animal drug applications (NADA's). Patent term expiration dates for certain patents that are subject to both the Uruguay Round Agreements Act (URAA) and the patent term extension provisions of the United States Code should be calculated in accordance with the Patent and Trademark Office's (PTO's) determination of June 7, 1995. FDA will not publish dates that the NDA or NADA applicant states are not calculated in accordance with the June 7, 1995, determination. This document is intended to advise all NDA and NADA applicants who submitted URAA-extended patent term expiration dates that were not calculated in accordance with the PTO's determination to submit corrected patent term expiration dates to the agency.

**DATES:** NDA and NADA applicants that submitted inaccurate patent term expiration dates should submit patent term expiration dates calculated in accordance with the PTO's determination by August 21, 1995.

**ADDRESSES:** Two copies of amended patent information pertaining to human drug products regulated under section 505 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355) by CDER should be submitted to the assigned reviewing division. The submission should bear the pertinent NDA number.

Two copies of amended patent information pertaining to human drug products regulated under section 505 of the act by CBER should be submitted to the Document Control Center, Center for Biologics Evaluation and Research (HFM-99), Food and Drug Administration, suite 200N, Rockville, MD 20852.

A third copy of the amended patent information pertaining to human drug products regulated under section 505 of the act by either the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER) should be sent to the Division of Drug Information Services (HFD-85), Center for Drug Evaluation and Research, Food and Drug Administration, 1901 Chapman Ave., rm. 212, Rockville, MD 20852.

Amended patent information pertaining to animal drug products should be sent to the Document Control Unit, Center for Veterinary Medicine (HFV-199), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

**FOR FURTHER INFORMATION CONTACT:** Wayne H. Mitchell, Center for Drug Evaluation and Research (HFD-362), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1049.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of June 8, 1995 (60 FR 30309), FDA announced the availability of the agency's response to a citizen petition from Glaxo, Inc., requesting that FDA explain how the URAA affects the patent information submission and patent certification requirements for applications to market drug products under the act. In that notice, FDA directed that amended patent information, reflecting extended patent term expiration dates under the URAA, be submitted to FDA between June 8 and July 8, 1995.

On June 7, 1995, the PTO published a notice in the **Federal Register** (60 FR 30069) entitled "Determination of New Expiration Dates of Certain Patents" (the PTO's determination) that established the method for calculating the patent term expiration date for any patent subject to both the terms of the URAA and the patent term extension provisions at 35 U.S.C. 156. FDA has received from several NDA or NADA applicants submissions of new patent term expiration dates which the applicant submitting the information states were not calculated in accordance with the PTO's determination. In order to comply with the requirements of sections 505(b) and 512(b) (21 U.S.C. 360b(b)) of the act and 21 CFR 314.53, NDA and NADA applicants must submit accurate patent information. For the expiration dates for patents that received patent term extension under the URAA to be accurate, those dates must be calculated in accordance with the PTO's determination.

FDA is advising all NDA and NADA applicants who submitted URAA-

extended patent term expiration dates that were not calculated in accordance with the PTO's determination to submit corrected patent term expiration dates to the agency by August 21, 1995. If the applicant has already submitted patent expiration dates that are consistent with the PTO's determination, no additional submission is necessary. FDA will not verify the patent expiration dates submitted by NDA and NADA applicants. FDA will not publish any patent expiration date that the submitter states is not consistent with the PTO's determination.

The agency will publish the new patent term expiration dates submitted during the June 8 to July 8, 1995, period that are not expressly identified by the applicant submitting the information as having been calculated in a manner inconsistent with the PTO's determination. FDA anticipates that the procedures set out in § 314.53(f) will govern with respect to challenges by third parties that the submitted patent term expiration date was not calculated in accordance with the PTO's determination. For these challenges, the procedures set out in § 314.53(f) will be modified so that, if the applicant submitting the challenged patent term expiration date fails to notify FDA within 30 days of receiving notification from the agency of a challenge to the patent that the submitted date is consistent with the PTO's determination, FDA will not continue to publish the challenged date.

Two copies of amended patent information pertaining to human drug products regulated under section 505 of the act by CDER should be submitted to the assigned reviewing division. The submission should bear the pertinent NDA number.

Two copies of amended patent information pertaining to human drug products regulated under section 505 of the act by CBER should be submitted to the Document Control Center, Center for Biologics Evaluation and Research (HFM-99), Food and Drug Administration, suite 200N, Rockville, MD 20852.

To expedite the availability to the public of the updated patent information, a third copy of the amended patent information pertaining to human drug products regulated under section 505 of the act by either CDER or CBER should be sent to the Division of Drug Information Services (HFD-85), Center for Drug Evaluation and Research, Food and Drug Administration, 1901 Chapman Ave., rm. 212, Rockville, MD 20852.

Amended patent information pertaining to animal drug products